Advertisement

Topics

Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylvania, As Sixth Trial Kicks Off in Philadelphia, Bernstein Liebhard LLP Reports

08:33 EDT 7 Aug 2017 | PR Newswire

NEW YORK, Aug. 7, 2017 /PRNewswire/ -- A Pennsylvania jury is now hearing evidence in the state's sixth trial involving allegedly defective transvaginal mesh devices marketed by Johnson & Johnson and its Ethicon, Inc. subsidiary. According to court documents pending in the Philadelphia Court of Common Pleas, this latest case was filed on behalf of a woman who claims that two of the companies' allegedly defective implants caused her to suffer painful and permanent complications, including damage to her urethra that resulted in incontinence. (In Re: Pelvic Mesh Litigation, Case No. 140200829)

"Our Firm is representing hundreds of women who allegedly experienced similar problems due to pelvic mesh devices manufactured by Ethicon and other companies. We will monitor this trial closely, as the verdict could provide clues as to how other juries will rule in similar transvaginal mesh lawsuits," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate potential legal claims on behalf of women who allegedly developed life-changing complications following implantation of transvaginal mesh.

Ethicon Transvaginal Mesh Litigation

Johnson & Johnson and Ethicon have been named defendants in more than 55,000 transvaginal mesh lawsuits pending nationwide. Women pursuing these claims say they experienced a wide range of painful complications, including the erosion of mesh into the vaginal wall, adhesions and scarring, chronic infections, permanent pain, and incontinence, due to the allegedly faulty implants. They further allege that Ethicon and Johnson & Johnson were aware of these defects, but failed to provide patients and doctors with appropriate warning regarding these risks.

So far, Johnson & Johnson and Ethicon have won only one transvaginal mesh trial in Pennsylvania. The first to involve the companies' devices concluded in December 2015, with a $12.5 million verdict for the plaintiffs. In February 2016, a second Pennsylvania jury awarded $13.6 million to another plaintiff, including $10 million in punitive damage. A third case concluded this past April, when Johnson & Johnson and Ethicon were ordered to pay a $20 million judgment, including $17.5 million in punitive damages.

The defendants' sole victory came in June.  However, that win was placed in jeopardy last month, when the Court granted the plaintiff's post-trial motion for a new damages hearing.

Transvaginal mesh devices are indicated to treat women who suffer from pelvic organ prolapse and stress urinary incontinence. In 2008, the U.S. Food & Drug Administration (FDA) warned that such devices had been associated with at least 1,000 reports of serious injuries and complications over a three-year period. In July 2011, the agency reported that complications related to transvaginal prolapse repair had tripled since the release of its previous warning. Among other things, the FDA reversed its stance that such injuries were rare.

In 2016, the FDA finalized regulations that reclassified pelvic mesh indicated for transvaginal prolapse repair as Class III (high risk) medical devices. The new rules also made transvaginal mesh ineligible for the agency's 510(k) clearance program, which had previously allowed such products to come to market without first undergoing human clinical trial

Women who suffered serious complications allegedly associated with transvaginal mesh may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no-obligation review of your potential claim.

About Bernstein Liebhard LLP 
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs' firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
800-511-5092

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/   
https://plus.google.com/115936073311125306742?rel=author

View original content:http://www.prnewswire.com/news-releases/ethicon-transvaginal-mesh-lawsuits-move-forward-in-pennsylvania-as-sixth-trial-kicks-off-in-philadelphia-bernstein-liebhard-llp-reports-300500365.html

SOURCE Bernstein Liebhard LLP

NEXT ARTICLE

More From BioPortfolio on "Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylvania, As Sixth Trial Kicks Off in Philadelphia, Bernstein Liebhard LLP Reports"

Quick Search
Advertisement
 

Relevant Topics

Hearing
Hearing, auditory perception, or audition is the ability to perceive sound by detecting vibrations, changes in the pressure of the surrounding medium through time, through an organ such as the ear. Sound may be heard through solid, liquid, or gaseous mat...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...